nodes	percent_of_prediction	percent_of_DWPC	metapath
Nicardipine—CYP2C8—Vismodegib—skin cancer	0.0799	0.126	CbGbCtD
Nicardipine—CYP2C19—Vismodegib—skin cancer	0.067	0.105	CbGbCtD
Nicardipine—CYP2E1—Dacarbazine—skin cancer	0.0648	0.102	CbGbCtD
Nicardipine—CYP2C9—Vismodegib—skin cancer	0.0557	0.0876	CbGbCtD
Nicardipine—ABCB1—Vismodegib—skin cancer	0.0541	0.085	CbGbCtD
Nicardipine—CYP3A4—Temozolomide—skin cancer	0.0467	0.0735	CbGbCtD
Nicardipine—CYP3A4—Imiquimod—skin cancer	0.0467	0.0735	CbGbCtD
Nicardipine—CYP2D6—Vemurafenib—skin cancer	0.0403	0.0633	CbGbCtD
Nicardipine—CYP3A4—Vismodegib—skin cancer	0.0324	0.051	CbGbCtD
Nicardipine—ABCB1—Dactinomycin—skin cancer	0.0284	0.0447	CbGbCtD
Nicardipine—CYP2C8—Fluorouracil—skin cancer	0.0284	0.0446	CbGbCtD
Nicardipine—CYP3A4—Vemurafenib—skin cancer	0.0256	0.0403	CbGbCtD
Nicardipine—CYP3A5—Docetaxel—skin cancer	0.0225	0.0354	CbGbCtD
Nicardipine—CYP2C9—Fluorouracil—skin cancer	0.0198	0.0311	CbGbCtD
Nicardipine—ABCB1—Docetaxel—skin cancer	0.0147	0.0231	CbGbCtD
Nicardipine—CYP3A4—Docetaxel—skin cancer	0.00878	0.0138	CbGbCtD
Nicardipine—CHRM3—muscle of abdomen—skin cancer	0.00707	0.0757	CbGeAlD
Nicardipine—CACNA1D—ear—skin cancer	0.00564	0.0604	CbGeAlD
Nicardipine—CHRM5—skin epidermis—skin cancer	0.00462	0.0495	CbGeAlD
Nicardipine—CALM2—ear—skin cancer	0.00342	0.0367	CbGeAlD
Nicardipine—CALM1—ear—skin cancer	0.00341	0.0365	CbGeAlD
Nicardipine—CALM2—nerve—skin cancer	0.00215	0.0231	CbGeAlD
Nicardipine—CALM1—nerve—skin cancer	0.00214	0.023	CbGeAlD
Nicardipine—PDE1B—female reproductive system—skin cancer	0.00187	0.02	CbGeAlD
Nicardipine—CALM2—endothelium—skin cancer	0.00183	0.0197	CbGeAlD
Nicardipine—CALM1—endothelium—skin cancer	0.00183	0.0196	CbGeAlD
Nicardipine—CALM2—hair follicle—skin cancer	0.0018	0.0193	CbGeAlD
Nicardipine—CALM2—blood vessel—skin cancer	0.00169	0.0181	CbGeAlD
Nicardipine—CALM1—blood vessel—skin cancer	0.00168	0.0181	CbGeAlD
Nicardipine—PDE1A—female reproductive system—skin cancer	0.00156	0.0168	CbGeAlD
Nicardipine—PDE1B—head—skin cancer	0.00156	0.0167	CbGeAlD
Nicardipine—CALM3—nipple—skin cancer	0.00156	0.0167	CbGeAlD
Nicardipine—CHRM5—epithelium—skin cancer	0.0015	0.0161	CbGeAlD
Nicardipine—CHRM5—skin of body—skin cancer	0.00143	0.0153	CbGeAlD
Nicardipine—ADRA1D—epithelium—skin cancer	0.00134	0.0144	CbGeAlD
Nicardipine—CACNA1C—connective tissue—skin cancer	0.00132	0.0141	CbGeAlD
Nicardipine—PDE1A—head—skin cancer	0.00131	0.014	CbGeAlD
Nicardipine—CALM2—nipple—skin cancer	0.00122	0.0131	CbGeAlD
Nicardipine—CALM1—nipple—skin cancer	0.00122	0.013	CbGeAlD
Nicardipine—CALM2—neck—skin cancer	0.00121	0.013	CbGeAlD
Nicardipine—CALM1—neck—skin cancer	0.0012	0.0129	CbGeAlD
Nicardipine—CHRM4—head—skin cancer	0.00119	0.0128	CbGeAlD
Nicardipine—PDE1B—lymph node—skin cancer	0.00109	0.0117	CbGeAlD
Nicardipine—Sinusitis—Imiquimod—skin cancer	0.00106	0.00641	CcSEcCtD
Nicardipine—Abnormal vision—Temozolomide—skin cancer	0.00105	0.00639	CcSEcCtD
Nicardipine—Rhinitis—Imiquimod—skin cancer	0.00102	0.00615	CcSEcCtD
Nicardipine—ADRA1D—female reproductive system—skin cancer	0.000999	0.0107	CbGeAlD
Nicardipine—Asthenia—Vismodegib—skin cancer	0.00098	0.00594	CcSEcCtD
Nicardipine—Visual impairment—Imiquimod—skin cancer	0.000976	0.00591	CcSEcCtD
Nicardipine—CACNB2—head—skin cancer	0.000963	0.0103	CbGeAlD
Nicardipine—Tinnitus—Imiquimod—skin cancer	0.000945	0.00572	CcSEcCtD
Nicardipine—Flushing—Imiquimod—skin cancer	0.00094	0.00569	CcSEcCtD
Nicardipine—Hot flush—Temozolomide—skin cancer	0.000938	0.00568	CcSEcCtD
Nicardipine—Diarrhoea—Vismodegib—skin cancer	0.000935	0.00566	CcSEcCtD
Nicardipine—CHRM5—head—skin cancer	0.000934	0.01	CbGeAlD
Nicardipine—CACNA1C—female reproductive system—skin cancer	0.00093	0.00997	CbGeAlD
Nicardipine—Menopausal symptoms—Temozolomide—skin cancer	0.00093	0.00563	CcSEcCtD
Nicardipine—PDE1A—lymph node—skin cancer	0.000915	0.0098	CbGeAlD
Nicardipine—CALM3—mammalian vulva—skin cancer	0.00091	0.00975	CbGeAlD
Nicardipine—CACNA2D1—head—skin cancer	0.000904	0.00969	CbGeAlD
Nicardipine—Oropharyngeal pain—Docetaxel—skin cancer	0.000884	0.00536	CcSEcCtD
Nicardipine—Arthralgia—Vemurafenib—skin cancer	0.00088	0.00533	CcSEcCtD
Nicardipine—Myalgia—Vemurafenib—skin cancer	0.00088	0.00533	CcSEcCtD
Nicardipine—Vomiting—Vismodegib—skin cancer	0.000869	0.00526	CcSEcCtD
Nicardipine—CALM2—connective tissue—skin cancer	0.000867	0.0093	CbGeAlD
Nicardipine—CALM1—connective tissue—skin cancer	0.000863	0.00926	CbGeAlD
Nicardipine—Rash—Vismodegib—skin cancer	0.000861	0.00522	CcSEcCtD
Nicardipine—Dermatitis—Vismodegib—skin cancer	0.00086	0.00521	CcSEcCtD
Nicardipine—ADRA1B—head—skin cancer	0.000853	0.00915	CbGeAlD
Nicardipine—Face oedema—Temozolomide—skin cancer	0.000847	0.00513	CcSEcCtD
Nicardipine—CACNA1D—head—skin cancer	0.000842	0.00902	CbGeAlD
Nicardipine—Infection—Vemurafenib—skin cancer	0.000838	0.00508	CcSEcCtD
Nicardipine—ADRA1D—head—skin cancer	0.000835	0.00895	CbGeAlD
Nicardipine—CALM2—epithelium—skin cancer	0.000823	0.00883	CbGeAlD
Nicardipine—CALM1—epithelium—skin cancer	0.00082	0.00879	CbGeAlD
Nicardipine—Ill-defined disorder—Imiquimod—skin cancer	0.000818	0.00496	CcSEcCtD
Nicardipine—Nausea—Vismodegib—skin cancer	0.000811	0.00491	CcSEcCtD
Nicardipine—Agitation—Imiquimod—skin cancer	0.00081	0.00491	CcSEcCtD
Nicardipine—Injection site reaction—Docetaxel—skin cancer	0.000799	0.00484	CcSEcCtD
Nicardipine—Hypokalaemia—Temozolomide—skin cancer	0.000799	0.00484	CcSEcCtD
Nicardipine—Malaise—Imiquimod—skin cancer	0.000795	0.00482	CcSEcCtD
Nicardipine—Syncope—Imiquimod—skin cancer	0.000791	0.00479	CcSEcCtD
Nicardipine—Acute coronary syndrome—Bleomycin—skin cancer	0.00079	0.00479	CcSEcCtD
Nicardipine—Hypotension—Vemurafenib—skin cancer	0.000789	0.00478	CcSEcCtD
Nicardipine—Myocardial infarction—Bleomycin—skin cancer	0.000786	0.00476	CcSEcCtD
Nicardipine—CALM2—skin of body—skin cancer	0.000783	0.0084	CbGeAlD
Nicardipine—CALM1—skin of body—skin cancer	0.00078	0.00836	CbGeAlD
Nicardipine—Palpitations—Imiquimod—skin cancer	0.000779	0.00472	CcSEcCtD
Nicardipine—CACNA1C—head—skin cancer	0.000777	0.00833	CbGeAlD
Nicardipine—Loss of consciousness—Imiquimod—skin cancer	0.000775	0.00469	CcSEcCtD
Nicardipine—ADRA1A—epithelium—skin cancer	0.000772	0.00828	CbGeAlD
Nicardipine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000769	0.00466	CcSEcCtD
Nicardipine—Haematuria—Bleomycin—skin cancer	0.000764	0.00463	CcSEcCtD
Nicardipine—Hypertension—Imiquimod—skin cancer	0.000761	0.00461	CcSEcCtD
Nicardipine—Arthralgia—Imiquimod—skin cancer	0.000751	0.00455	CcSEcCtD
Nicardipine—Myalgia—Imiquimod—skin cancer	0.000751	0.00455	CcSEcCtD
Nicardipine—Chest pain—Imiquimod—skin cancer	0.000751	0.00455	CcSEcCtD
Nicardipine—Anxiety—Imiquimod—skin cancer	0.000748	0.00453	CcSEcCtD
Nicardipine—Discomfort—Imiquimod—skin cancer	0.000742	0.00449	CcSEcCtD
Nicardipine—Sweating increased—Temozolomide—skin cancer	0.000739	0.00448	CcSEcCtD
Nicardipine—Dry mouth—Imiquimod—skin cancer	0.000734	0.00445	CcSEcCtD
Nicardipine—Constipation—Vemurafenib—skin cancer	0.000722	0.00437	CcSEcCtD
Nicardipine—Oedema—Imiquimod—skin cancer	0.00072	0.00436	CcSEcCtD
Nicardipine—Hypoaesthesia—Bleomycin—skin cancer	0.000716	0.00434	CcSEcCtD
Nicardipine—Infection—Imiquimod—skin cancer	0.000715	0.00433	CcSEcCtD
Nicardipine—CALM2—mammalian vulva—skin cancer	0.000714	0.00766	CbGeAlD
Nicardipine—CALM1—mammalian vulva—skin cancer	0.000711	0.00762	CbGeAlD
Nicardipine—Shock—Imiquimod—skin cancer	0.000708	0.00429	CcSEcCtD
Nicardipine—Tachycardia—Imiquimod—skin cancer	0.000702	0.00425	CcSEcCtD
Nicardipine—Pollakiuria—Temozolomide—skin cancer	0.000701	0.00424	CcSEcCtD
Nicardipine—Erectile dysfunction—Temozolomide—skin cancer	0.000699	0.00423	CcSEcCtD
Nicardipine—CHRM1—female reproductive system—skin cancer	0.000698	0.00749	CbGeAlD
Nicardipine—Hyperhidrosis—Imiquimod—skin cancer	0.000696	0.00421	CcSEcCtD
Nicardipine—Angina pectoris—Fluorouracil—skin cancer	0.000681	0.00412	CcSEcCtD
Nicardipine—CACNB2—lymph node—skin cancer	0.000674	0.00723	CbGeAlD
Nicardipine—ABCB1—blood vessel—skin cancer	0.000672	0.00721	CbGeAlD
Nicardipine—Flushing—Bleomycin—skin cancer	0.000668	0.00405	CcSEcCtD
Nicardipine—Body temperature increased—Vemurafenib—skin cancer	0.000667	0.00404	CcSEcCtD
Nicardipine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000656	0.00397	CcSEcCtD
Nicardipine—Insomnia—Imiquimod—skin cancer	0.000651	0.00394	CcSEcCtD
Nicardipine—Paraesthesia—Imiquimod—skin cancer	0.000646	0.00391	CcSEcCtD
Nicardipine—Dyspnoea—Imiquimod—skin cancer	0.000642	0.00389	CcSEcCtD
Nicardipine—CHRM2—head—skin cancer	0.000641	0.00687	CbGeAlD
Nicardipine—Somnolence—Imiquimod—skin cancer	0.00064	0.00388	CcSEcCtD
Nicardipine—Sinusitis—Temozolomide—skin cancer	0.000634	0.00384	CcSEcCtD
Nicardipine—CALM2—lymphoid tissue—skin cancer	0.000634	0.0068	CbGeAlD
Nicardipine—Dyspepsia—Imiquimod—skin cancer	0.000634	0.00384	CcSEcCtD
Nicardipine—CACNA2D1—lymph node—skin cancer	0.000633	0.00679	CbGeAlD
Nicardipine—CALM1—lymphoid tissue—skin cancer	0.000631	0.00677	CbGeAlD
Nicardipine—CHRM3—female reproductive system—skin cancer	0.000625	0.0067	CbGeAlD
Nicardipine—Hot flush—Docetaxel—skin cancer	0.000624	0.00378	CcSEcCtD
Nicardipine—Flushing—Dactinomycin—skin cancer	0.000623	0.00377	CcSEcCtD
Nicardipine—Hypersensitivity—Vemurafenib—skin cancer	0.000622	0.00377	CcSEcCtD
Nicardipine—Menopausal symptoms—Docetaxel—skin cancer	0.000618	0.00375	CcSEcCtD
Nicardipine—Atrial fibrillation—Docetaxel—skin cancer	0.000616	0.00373	CcSEcCtD
Nicardipine—Pain—Imiquimod—skin cancer	0.000615	0.00373	CcSEcCtD
Nicardipine—Acute coronary syndrome—Fluorouracil—skin cancer	0.000614	0.00372	CcSEcCtD
Nicardipine—CALM2—female reproductive system—skin cancer	0.000612	0.00656	CbGeAlD
Nicardipine—Myocardial infarction—Fluorouracil—skin cancer	0.000611	0.0037	CcSEcCtD
Nicardipine—CALM1—female reproductive system—skin cancer	0.000609	0.00653	CbGeAlD
Nicardipine—Conjunctivitis—Fluorouracil—skin cancer	0.000606	0.00367	CcSEcCtD
Nicardipine—Asthenia—Vemurafenib—skin cancer	0.000605	0.00367	CcSEcCtD
Nicardipine—Hypoaesthesia—Temozolomide—skin cancer	0.000604	0.00366	CcSEcCtD
Nicardipine—Oedema peripheral—Temozolomide—skin cancer	0.000598	0.00362	CcSEcCtD
Nicardipine—ADRA1A—lymphoid tissue—skin cancer	0.000595	0.00638	CbGeAlD
Nicardipine—Feeling abnormal—Imiquimod—skin cancer	0.000593	0.00359	CcSEcCtD
Nicardipine—CACNA1D—lymph node—skin cancer	0.000589	0.00632	CbGeAlD
Nicardipine—Gastrointestinal pain—Imiquimod—skin cancer	0.000589	0.00356	CcSEcCtD
Nicardipine—Visual impairment—Temozolomide—skin cancer	0.000585	0.00354	CcSEcCtD
Nicardipine—Sinusitis—Fluorouracil—skin cancer	0.000585	0.00354	CcSEcCtD
Nicardipine—CHRM1—head—skin cancer	0.000583	0.00625	CbGeAlD
Nicardipine—CYP2B6—skin of body—skin cancer	0.000582	0.00624	CbGeAlD
Nicardipine—Ill-defined disorder—Bleomycin—skin cancer	0.000581	0.00352	CcSEcCtD
Nicardipine—Diarrhoea—Vemurafenib—skin cancer	0.000577	0.0035	CcSEcCtD
Nicardipine—Abdominal pain—Imiquimod—skin cancer	0.000569	0.00345	CcSEcCtD
Nicardipine—Body temperature increased—Imiquimod—skin cancer	0.000569	0.00345	CcSEcCtD
Nicardipine—Tinnitus—Temozolomide—skin cancer	0.000566	0.00343	CcSEcCtD
Nicardipine—Malaise—Bleomycin—skin cancer	0.000565	0.00342	CcSEcCtD
Nicardipine—Flushing—Temozolomide—skin cancer	0.000563	0.00341	CcSEcCtD
Nicardipine—Rhinitis—Fluorouracil—skin cancer	0.000561	0.0034	CcSEcCtD
Nicardipine—Dizziness—Vemurafenib—skin cancer	0.000558	0.00338	CcSEcCtD
Nicardipine—Hypoaesthesia—Fluorouracil—skin cancer	0.000557	0.00337	CcSEcCtD
Nicardipine—CACNA1C—lymph node—skin cancer	0.000544	0.00583	CbGeAlD
Nicardipine—Ill-defined disorder—Dactinomycin—skin cancer	0.000542	0.00328	CcSEcCtD
Nicardipine—Vomiting—Vemurafenib—skin cancer	0.000537	0.00325	CcSEcCtD
Nicardipine—Chest pain—Bleomycin—skin cancer	0.000533	0.00323	CcSEcCtD
Nicardipine—Myalgia—Bleomycin—skin cancer	0.000533	0.00323	CcSEcCtD
Nicardipine—Orthostatic hypotension—Docetaxel—skin cancer	0.000533	0.00323	CcSEcCtD
Nicardipine—Rash—Vemurafenib—skin cancer	0.000532	0.00322	CcSEcCtD
Nicardipine—Dermatitis—Vemurafenib—skin cancer	0.000532	0.00322	CcSEcCtD
Nicardipine—Hypersensitivity—Imiquimod—skin cancer	0.00053	0.00321	CcSEcCtD
Nicardipine—Headache—Vemurafenib—skin cancer	0.000529	0.0032	CcSEcCtD
Nicardipine—Discomfort—Bleomycin—skin cancer	0.000527	0.00319	CcSEcCtD
Nicardipine—Malaise—Dactinomycin—skin cancer	0.000527	0.00319	CcSEcCtD
Nicardipine—CHRM3—head—skin cancer	0.000522	0.0056	CbGeAlD
Nicardipine—Asthenia—Imiquimod—skin cancer	0.000516	0.00313	CcSEcCtD
Nicardipine—Confusional state—Bleomycin—skin cancer	0.000516	0.00312	CcSEcCtD
Nicardipine—Oedema—Bleomycin—skin cancer	0.000511	0.0031	CcSEcCtD
Nicardipine—CALM2—head—skin cancer	0.000511	0.00548	CbGeAlD
Nicardipine—CALM1—head—skin cancer	0.000509	0.00545	CbGeAlD
Nicardipine—Infection—Bleomycin—skin cancer	0.000508	0.00308	CcSEcCtD
Nicardipine—CYP2C8—female reproductive system—skin cancer	0.000507	0.00543	CbGeAlD
Nicardipine—Nausea—Vemurafenib—skin cancer	0.000501	0.00304	CcSEcCtD
Nicardipine—Thrombocytopenia—Bleomycin—skin cancer	0.000501	0.00303	CcSEcCtD
Nicardipine—Vision blurred—Temozolomide—skin cancer	0.000498	0.00302	CcSEcCtD
Nicardipine—Myalgia—Dactinomycin—skin cancer	0.000497	0.00301	CcSEcCtD
Nicardipine—Tremor—Temozolomide—skin cancer	0.000495	0.003	CcSEcCtD
Nicardipine—Diarrhoea—Imiquimod—skin cancer	0.000492	0.00298	CcSEcCtD
Nicardipine—Discomfort—Dactinomycin—skin cancer	0.000491	0.00298	CcSEcCtD
Nicardipine—Angina pectoris—Docetaxel—skin cancer	0.000491	0.00298	CcSEcCtD
Nicardipine—Ill-defined disorder—Temozolomide—skin cancer	0.00049	0.00297	CcSEcCtD
Nicardipine—Agitation—Temozolomide—skin cancer	0.000486	0.00294	CcSEcCtD
Nicardipine—ADRA1A—head—skin cancer	0.000479	0.00514	CbGeAlD
Nicardipine—Hypotension—Bleomycin—skin cancer	0.000478	0.00289	CcSEcCtD
Nicardipine—Oedema—Dactinomycin—skin cancer	0.000477	0.00289	CcSEcCtD
Nicardipine—Malaise—Temozolomide—skin cancer	0.000477	0.00289	CcSEcCtD
Nicardipine—Dizziness—Imiquimod—skin cancer	0.000476	0.00288	CcSEcCtD
Nicardipine—Vertigo—Temozolomide—skin cancer	0.000475	0.00288	CcSEcCtD
Nicardipine—Infection—Dactinomycin—skin cancer	0.000474	0.00287	CcSEcCtD
Nicardipine—CYP2B6—lymphoid tissue—skin cancer	0.000472	0.00505	CbGeAlD
Nicardipine—Palpitations—Temozolomide—skin cancer	0.000467	0.00283	CcSEcCtD
Nicardipine—Thrombocytopenia—Dactinomycin—skin cancer	0.000467	0.00283	CcSEcCtD
Nicardipine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000466	0.00282	CcSEcCtD
Nicardipine—Paraesthesia—Bleomycin—skin cancer	0.000459	0.00278	CcSEcCtD
Nicardipine—Vision blurred—Fluorouracil—skin cancer	0.000459	0.00278	CcSEcCtD
Nicardipine—Vomiting—Imiquimod—skin cancer	0.000458	0.00277	CcSEcCtD
Nicardipine—Hypertension—Temozolomide—skin cancer	0.000456	0.00276	CcSEcCtD
Nicardipine—Dyspnoea—Bleomycin—skin cancer	0.000456	0.00276	CcSEcCtD
Nicardipine—CALM3—lymph node—skin cancer	0.000456	0.00488	CbGeAlD
Nicardipine—CYP2B6—female reproductive system—skin cancer	0.000455	0.00487	CbGeAlD
Nicardipine—Rash—Imiquimod—skin cancer	0.000454	0.00275	CcSEcCtD
Nicardipine—Dermatitis—Imiquimod—skin cancer	0.000453	0.00275	CcSEcCtD
Nicardipine—Headache—Imiquimod—skin cancer	0.000451	0.00273	CcSEcCtD
Nicardipine—CYP2C9—female reproductive system—skin cancer	0.00045	0.00483	CbGeAlD
Nicardipine—Myalgia—Temozolomide—skin cancer	0.00045	0.00273	CcSEcCtD
Nicardipine—Arthralgia—Temozolomide—skin cancer	0.00045	0.00273	CcSEcCtD
Nicardipine—Anxiety—Temozolomide—skin cancer	0.000448	0.00272	CcSEcCtD
Nicardipine—Discomfort—Temozolomide—skin cancer	0.000445	0.00269	CcSEcCtD
Nicardipine—Acute coronary syndrome—Docetaxel—skin cancer	0.000443	0.00269	CcSEcCtD
Nicardipine—CYP2E1—lymphoid tissue—skin cancer	0.000442	0.00474	CbGeAlD
Nicardipine—Myocardial infarction—Docetaxel—skin cancer	0.000441	0.00267	CcSEcCtD
Nicardipine—Dry mouth—Temozolomide—skin cancer	0.00044	0.00267	CcSEcCtD
Nicardipine—Pain—Bleomycin—skin cancer	0.000437	0.00265	CcSEcCtD
Nicardipine—Conjunctivitis—Docetaxel—skin cancer	0.000437	0.00265	CcSEcCtD
Nicardipine—Confusional state—Temozolomide—skin cancer	0.000435	0.00263	CcSEcCtD
Nicardipine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000434	0.00263	CcSEcCtD
Nicardipine—Oedema—Temozolomide—skin cancer	0.000431	0.00261	CcSEcCtD
Nicardipine—Infection—Temozolomide—skin cancer	0.000428	0.0026	CcSEcCtD
Nicardipine—Nausea—Imiquimod—skin cancer	0.000427	0.00259	CcSEcCtD
Nicardipine—CYP2E1—female reproductive system—skin cancer	0.000427	0.00457	CbGeAlD
Nicardipine—Thrombocytopenia—Temozolomide—skin cancer	0.000422	0.00256	CcSEcCtD
Nicardipine—Feeling abnormal—Bleomycin—skin cancer	0.000421	0.00255	CcSEcCtD
Nicardipine—Hyperhidrosis—Temozolomide—skin cancer	0.000417	0.00253	CcSEcCtD
Nicardipine—Chest pain—Fluorouracil—skin cancer	0.000415	0.00251	CcSEcCtD
Nicardipine—Myalgia—Fluorouracil—skin cancer	0.000415	0.00251	CcSEcCtD
Nicardipine—Discomfort—Fluorouracil—skin cancer	0.00041	0.00248	CcSEcCtD
Nicardipine—Pain—Dactinomycin—skin cancer	0.000408	0.00247	CcSEcCtD
Nicardipine—Rhinitis—Docetaxel—skin cancer	0.000405	0.00245	CcSEcCtD
Nicardipine—Body temperature increased—Bleomycin—skin cancer	0.000404	0.00245	CcSEcCtD
Nicardipine—Hypoaesthesia—Docetaxel—skin cancer	0.000402	0.00243	CcSEcCtD
Nicardipine—Confusional state—Fluorouracil—skin cancer	0.000401	0.00243	CcSEcCtD
Nicardipine—Oedema peripheral—Docetaxel—skin cancer	0.000398	0.00241	CcSEcCtD
Nicardipine—Oedema—Fluorouracil—skin cancer	0.000397	0.00241	CcSEcCtD
Nicardipine—Infection—Fluorouracil—skin cancer	0.000395	0.00239	CcSEcCtD
Nicardipine—Feeling abnormal—Dactinomycin—skin cancer	0.000393	0.00238	CcSEcCtD
Nicardipine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000393	0.00238	CcSEcCtD
Nicardipine—Insomnia—Temozolomide—skin cancer	0.00039	0.00236	CcSEcCtD
Nicardipine—Gastrointestinal pain—Dactinomycin—skin cancer	0.00039	0.00236	CcSEcCtD
Nicardipine—Thrombocytopenia—Fluorouracil—skin cancer	0.000389	0.00236	CcSEcCtD
Nicardipine—Visual impairment—Docetaxel—skin cancer	0.000389	0.00236	CcSEcCtD
Nicardipine—Tachycardia—Fluorouracil—skin cancer	0.000388	0.00235	CcSEcCtD
Nicardipine—Paraesthesia—Temozolomide—skin cancer	0.000387	0.00235	CcSEcCtD
Nicardipine—Dyspnoea—Temozolomide—skin cancer	0.000385	0.00233	CcSEcCtD
Nicardipine—Somnolence—Temozolomide—skin cancer	0.000383	0.00232	CcSEcCtD
Nicardipine—CYP2B6—head—skin cancer	0.00038	0.00407	CbGeAlD
Nicardipine—Dyspepsia—Temozolomide—skin cancer	0.00038	0.0023	CcSEcCtD
Nicardipine—Abdominal pain—Dactinomycin—skin cancer	0.000377	0.00228	CcSEcCtD
Nicardipine—Body temperature increased—Dactinomycin—skin cancer	0.000377	0.00228	CcSEcCtD
Nicardipine—Hypersensitivity—Bleomycin—skin cancer	0.000377	0.00228	CcSEcCtD
Nicardipine—Flushing—Docetaxel—skin cancer	0.000375	0.00227	CcSEcCtD
Nicardipine—Hypotension—Fluorouracil—skin cancer	0.000371	0.00225	CcSEcCtD
Nicardipine—Pain—Temozolomide—skin cancer	0.000369	0.00223	CcSEcCtD
Nicardipine—Constipation—Temozolomide—skin cancer	0.000369	0.00223	CcSEcCtD
Nicardipine—Asthenia—Bleomycin—skin cancer	0.000367	0.00222	CcSEcCtD
Nicardipine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000362	0.00219	CcSEcCtD
Nicardipine—Insomnia—Fluorouracil—skin cancer	0.000359	0.00218	CcSEcCtD
Nicardipine—CALM2—lymph node—skin cancer	0.000358	0.00384	CbGeAlD
Nicardipine—Paraesthesia—Fluorouracil—skin cancer	0.000357	0.00216	CcSEcCtD
Nicardipine—CYP2E1—head—skin cancer	0.000357	0.00382	CbGeAlD
Nicardipine—CALM1—lymph node—skin cancer	0.000356	0.00382	CbGeAlD
Nicardipine—Feeling abnormal—Temozolomide—skin cancer	0.000355	0.00215	CcSEcCtD
Nicardipine—Dyspnoea—Fluorouracil—skin cancer	0.000354	0.00215	CcSEcCtD
Nicardipine—Somnolence—Fluorouracil—skin cancer	0.000353	0.00214	CcSEcCtD
Nicardipine—Gastrointestinal pain—Temozolomide—skin cancer	0.000353	0.00214	CcSEcCtD
Nicardipine—Hypersensitivity—Dactinomycin—skin cancer	0.000351	0.00213	CcSEcCtD
Nicardipine—Dyspepsia—Fluorouracil—skin cancer	0.00035	0.00212	CcSEcCtD
Nicardipine—CYP3A4—female reproductive system—skin cancer	0.000343	0.00368	CbGeAlD
Nicardipine—Asthenia—Dactinomycin—skin cancer	0.000342	0.00207	CcSEcCtD
Nicardipine—Abdominal pain—Temozolomide—skin cancer	0.000341	0.00207	CcSEcCtD
Nicardipine—Body temperature increased—Temozolomide—skin cancer	0.000341	0.00207	CcSEcCtD
Nicardipine—Pain—Fluorouracil—skin cancer	0.00034	0.00206	CcSEcCtD
Nicardipine—CYP2D6—female reproductive system—skin cancer	0.000338	0.00362	CbGeAlD
Nicardipine—Feeling abnormal—Fluorouracil—skin cancer	0.000327	0.00198	CcSEcCtD
Nicardipine—ABCB1—epithelium—skin cancer	0.000327	0.00351	CbGeAlD
Nicardipine—Diarrhoea—Dactinomycin—skin cancer	0.000326	0.00198	CcSEcCtD
Nicardipine—Vomiting—Bleomycin—skin cancer	0.000325	0.00197	CcSEcCtD
Nicardipine—Rash—Bleomycin—skin cancer	0.000322	0.00195	CcSEcCtD
Nicardipine—Dermatitis—Bleomycin—skin cancer	0.000322	0.00195	CcSEcCtD
Nicardipine—Hypersensitivity—Temozolomide—skin cancer	0.000318	0.00192	CcSEcCtD
Nicardipine—Syncope—Docetaxel—skin cancer	0.000315	0.00191	CcSEcCtD
Nicardipine—Body temperature increased—Fluorouracil—skin cancer	0.000314	0.0019	CcSEcCtD
Nicardipine—Palpitations—Docetaxel—skin cancer	0.000311	0.00188	CcSEcCtD
Nicardipine—Asthenia—Temozolomide—skin cancer	0.000309	0.00187	CcSEcCtD
Nicardipine—Loss of consciousness—Docetaxel—skin cancer	0.000309	0.00187	CcSEcCtD
Nicardipine—Nausea—Bleomycin—skin cancer	0.000304	0.00184	CcSEcCtD
Nicardipine—Hypertension—Docetaxel—skin cancer	0.000303	0.00184	CcSEcCtD
Nicardipine—Vomiting—Dactinomycin—skin cancer	0.000303	0.00184	CcSEcCtD
Nicardipine—Rash—Dactinomycin—skin cancer	0.000301	0.00182	CcSEcCtD
Nicardipine—Myalgia—Docetaxel—skin cancer	0.000299	0.00181	CcSEcCtD
Nicardipine—Arthralgia—Docetaxel—skin cancer	0.000299	0.00181	CcSEcCtD
Nicardipine—Chest pain—Docetaxel—skin cancer	0.000299	0.00181	CcSEcCtD
Nicardipine—Diarrhoea—Temozolomide—skin cancer	0.000295	0.00179	CcSEcCtD
Nicardipine—Hypersensitivity—Fluorouracil—skin cancer	0.000293	0.00177	CcSEcCtD
Nicardipine—Dry mouth—Docetaxel—skin cancer	0.000293	0.00177	CcSEcCtD
Nicardipine—Confusional state—Docetaxel—skin cancer	0.000289	0.00175	CcSEcCtD
Nicardipine—Oedema—Docetaxel—skin cancer	0.000287	0.00174	CcSEcCtD
Nicardipine—Dizziness—Temozolomide—skin cancer	0.000285	0.00173	CcSEcCtD
Nicardipine—Infection—Docetaxel—skin cancer	0.000285	0.00173	CcSEcCtD
Nicardipine—ABCB1—mammalian vulva—skin cancer	0.000284	0.00304	CbGeAlD
Nicardipine—Nausea—Dactinomycin—skin cancer	0.000283	0.00172	CcSEcCtD
Nicardipine—CYP2D6—head—skin cancer	0.000282	0.00303	CbGeAlD
Nicardipine—Shock—Docetaxel—skin cancer	0.000282	0.00171	CcSEcCtD
Nicardipine—Thrombocytopenia—Docetaxel—skin cancer	0.000281	0.0017	CcSEcCtD
Nicardipine—Tachycardia—Docetaxel—skin cancer	0.00028	0.0017	CcSEcCtD
Nicardipine—Vomiting—Temozolomide—skin cancer	0.000274	0.00166	CcSEcCtD
Nicardipine—Rash—Temozolomide—skin cancer	0.000272	0.00165	CcSEcCtD
Nicardipine—Diarrhoea—Fluorouracil—skin cancer	0.000272	0.00165	CcSEcCtD
Nicardipine—Dermatitis—Temozolomide—skin cancer	0.000272	0.00165	CcSEcCtD
Nicardipine—Headache—Temozolomide—skin cancer	0.00027	0.00164	CcSEcCtD
Nicardipine—Hypotension—Docetaxel—skin cancer	0.000268	0.00162	CcSEcCtD
Nicardipine—Dizziness—Fluorouracil—skin cancer	0.000263	0.00159	CcSEcCtD
Nicardipine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000261	0.00158	CcSEcCtD
Nicardipine—Insomnia—Docetaxel—skin cancer	0.000259	0.00157	CcSEcCtD
Nicardipine—Paraesthesia—Docetaxel—skin cancer	0.000258	0.00156	CcSEcCtD
Nicardipine—Nausea—Temozolomide—skin cancer	0.000256	0.00155	CcSEcCtD
Nicardipine—Dyspnoea—Docetaxel—skin cancer	0.000256	0.00155	CcSEcCtD
Nicardipine—Somnolence—Docetaxel—skin cancer	0.000255	0.00154	CcSEcCtD
Nicardipine—Vomiting—Fluorouracil—skin cancer	0.000253	0.00153	CcSEcCtD
Nicardipine—Dyspepsia—Docetaxel—skin cancer	0.000252	0.00153	CcSEcCtD
Nicardipine—ABCB1—lymphoid tissue—skin cancer	0.000252	0.0027	CbGeAlD
Nicardipine—Rash—Fluorouracil—skin cancer	0.000251	0.00152	CcSEcCtD
Nicardipine—Dermatitis—Fluorouracil—skin cancer	0.00025	0.00152	CcSEcCtD
Nicardipine—Headache—Fluorouracil—skin cancer	0.000249	0.00151	CcSEcCtD
Nicardipine—Pain—Docetaxel—skin cancer	0.000245	0.00149	CcSEcCtD
Nicardipine—Constipation—Docetaxel—skin cancer	0.000245	0.00149	CcSEcCtD
Nicardipine—ABCB1—female reproductive system—skin cancer	0.000243	0.00261	CbGeAlD
Nicardipine—Feeling abnormal—Docetaxel—skin cancer	0.000236	0.00143	CcSEcCtD
Nicardipine—Nausea—Fluorouracil—skin cancer	0.000236	0.00143	CcSEcCtD
Nicardipine—Gastrointestinal pain—Docetaxel—skin cancer	0.000235	0.00142	CcSEcCtD
Nicardipine—Body temperature increased—Docetaxel—skin cancer	0.000227	0.00137	CcSEcCtD
Nicardipine—Abdominal pain—Docetaxel—skin cancer	0.000227	0.00137	CcSEcCtD
Nicardipine—Hypersensitivity—Docetaxel—skin cancer	0.000211	0.00128	CcSEcCtD
Nicardipine—Asthenia—Docetaxel—skin cancer	0.000206	0.00125	CcSEcCtD
Nicardipine—ABCB1—head—skin cancer	0.000203	0.00218	CbGeAlD
Nicardipine—Diarrhoea—Docetaxel—skin cancer	0.000196	0.00119	CcSEcCtD
Nicardipine—Dizziness—Docetaxel—skin cancer	0.00019	0.00115	CcSEcCtD
Nicardipine—Vomiting—Docetaxel—skin cancer	0.000182	0.0011	CcSEcCtD
Nicardipine—Rash—Docetaxel—skin cancer	0.000181	0.0011	CcSEcCtD
Nicardipine—Dermatitis—Docetaxel—skin cancer	0.000181	0.00109	CcSEcCtD
Nicardipine—Headache—Docetaxel—skin cancer	0.00018	0.00109	CcSEcCtD
Nicardipine—Nausea—Docetaxel—skin cancer	0.00017	0.00103	CcSEcCtD
Nicardipine—ABCB1—lymph node—skin cancer	0.000142	0.00152	CbGeAlD
Nicardipine—CALM1—Signaling Pathways—PTGER4—skin cancer	1.8e-05	0.000169	CbGpPWpGaD
Nicardipine—PDE1A—Signaling by GPCR—IL6—skin cancer	1.78e-05	0.000168	CbGpPWpGaD
Nicardipine—CALM3—Signaling by NGF—IL6—skin cancer	1.78e-05	0.000168	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling Pathways—TERT—skin cancer	1.75e-05	0.000165	CbGpPWpGaD
Nicardipine—CALM1—Signaling by NGF—IL6—skin cancer	1.72e-05	0.000162	CbGpPWpGaD
Nicardipine—CALM2—Signaling by NGF—IL6—skin cancer	1.72e-05	0.000162	CbGpPWpGaD
Nicardipine—CYP2D6—Metabolism—ENO2—skin cancer	1.72e-05	0.000162	CbGpPWpGaD
Nicardipine—CYP2C9—Metabolism—ENO2—skin cancer	1.7e-05	0.000161	CbGpPWpGaD
Nicardipine—PDE1B—Signaling by GPCR—HRAS—skin cancer	1.7e-05	0.000161	CbGpPWpGaD
Nicardipine—PDE1A—Immune System—HRAS—skin cancer	1.7e-05	0.00016	CbGpPWpGaD
Nicardipine—PDE1B—Disease—KRAS—skin cancer	1.69e-05	0.000159	CbGpPWpGaD
Nicardipine—CHRM3—Metabolism—ERCC2—skin cancer	1.67e-05	0.000157	CbGpPWpGaD
Nicardipine—CALM3—Disease—ERCC2—skin cancer	1.67e-05	0.000157	CbGpPWpGaD
Nicardipine—CYP3A4—Metabolism—CSPG4—skin cancer	1.65e-05	0.000156	CbGpPWpGaD
Nicardipine—CALM3—Signaling Pathways—FOXO4—skin cancer	1.64e-05	0.000155	CbGpPWpGaD
Nicardipine—CHRM4—Signaling by GPCR—NRAS—skin cancer	1.64e-05	0.000155	CbGpPWpGaD
Nicardipine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.64e-05	0.000154	CbGpPWpGaD
Nicardipine—PDE1B—Signaling by GPCR—IL6—skin cancer	1.63e-05	0.000154	CbGpPWpGaD
Nicardipine—PDE1A—Immune System—IL6—skin cancer	1.63e-05	0.000154	CbGpPWpGaD
Nicardipine—CALM1—Disease—ERCC2—skin cancer	1.61e-05	0.000152	CbGpPWpGaD
Nicardipine—CALM2—Disease—ERCC2—skin cancer	1.61e-05	0.000152	CbGpPWpGaD
Nicardipine—CALM3—Hemostasis—NRAS—skin cancer	1.61e-05	0.000152	CbGpPWpGaD
Nicardipine—CALM1—Signaling Pathways—FOXO4—skin cancer	1.59e-05	0.00015	CbGpPWpGaD
Nicardipine—CALM2—Signaling Pathways—FOXO4—skin cancer	1.59e-05	0.00015	CbGpPWpGaD
Nicardipine—PDE1A—Disease—HRAS—skin cancer	1.57e-05	0.000148	CbGpPWpGaD
Nicardipine—CHRM5—Signaling by GPCR—NRAS—skin cancer	1.57e-05	0.000148	CbGpPWpGaD
Nicardipine—CALM3—Disease—TERT—skin cancer	1.56e-05	0.000148	CbGpPWpGaD
Nicardipine—PDE1B—Immune System—HRAS—skin cancer	1.56e-05	0.000147	CbGpPWpGaD
Nicardipine—CALM2—Hemostasis—NRAS—skin cancer	1.56e-05	0.000147	CbGpPWpGaD
Nicardipine—CALM1—Hemostasis—NRAS—skin cancer	1.56e-05	0.000147	CbGpPWpGaD
Nicardipine—CHRM4—Signaling Pathways—BRAF—skin cancer	1.54e-05	0.000145	CbGpPWpGaD
Nicardipine—CALM2—Disease—TERT—skin cancer	1.51e-05	0.000143	CbGpPWpGaD
Nicardipine—CALM1—Disease—TERT—skin cancer	1.51e-05	0.000143	CbGpPWpGaD
Nicardipine—PDE1A—Signaling Pathways—NRAS—skin cancer	1.5e-05	0.000142	CbGpPWpGaD
Nicardipine—PDE1A—Disease—IL6—skin cancer	1.5e-05	0.000142	CbGpPWpGaD
Nicardipine—PDE1B—Immune System—IL6—skin cancer	1.49e-05	0.00014	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling by GPCR—NRAS—skin cancer	1.48e-05	0.000139	CbGpPWpGaD
Nicardipine—CHRM5—Signaling Pathways—BRAF—skin cancer	1.48e-05	0.000139	CbGpPWpGaD
Nicardipine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.46e-05	0.000138	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling Pathways—TERT—skin cancer	1.45e-05	0.000137	CbGpPWpGaD
Nicardipine—CALM3—Innate Immune System—NRAS—skin cancer	1.45e-05	0.000137	CbGpPWpGaD
Nicardipine—PDE1B—Disease—HRAS—skin cancer	1.44e-05	0.000135	CbGpPWpGaD
Nicardipine—CYP2B6—Metabolism—ERCC2—skin cancer	1.44e-05	0.000135	CbGpPWpGaD
Nicardipine—CHRM4—Signaling by GPCR—KRAS—skin cancer	1.41e-05	0.000133	CbGpPWpGaD
Nicardipine—CYP2E1—Metabolism—ERCC2—skin cancer	1.41e-05	0.000133	CbGpPWpGaD
Nicardipine—CYP3A5—Metabolism—ERCC2—skin cancer	1.4e-05	0.000132	CbGpPWpGaD
Nicardipine—CALM1—Innate Immune System—NRAS—skin cancer	1.4e-05	0.000132	CbGpPWpGaD
Nicardipine—CALM2—Innate Immune System—NRAS—skin cancer	1.4e-05	0.000132	CbGpPWpGaD
Nicardipine—CALM3—Metabolism—ERCC2—skin cancer	1.4e-05	0.000132	CbGpPWpGaD
Nicardipine—CALM3—Adaptive Immune System—NRAS—skin cancer	1.39e-05	0.000131	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling Pathways—BRAF—skin cancer	1.39e-05	0.000131	CbGpPWpGaD
Nicardipine—CALM3—Hemostasis—KRAS—skin cancer	1.38e-05	0.000131	CbGpPWpGaD
Nicardipine—PDE1B—Signaling Pathways—NRAS—skin cancer	1.37e-05	0.00013	CbGpPWpGaD
Nicardipine—PDE1B—Disease—IL6—skin cancer	1.37e-05	0.00013	CbGpPWpGaD
Nicardipine—CALM2—Metabolism—ERCC2—skin cancer	1.35e-05	0.000128	CbGpPWpGaD
Nicardipine—CALM1—Metabolism—ERCC2—skin cancer	1.35e-05	0.000128	CbGpPWpGaD
Nicardipine—CHRM5—Signaling by GPCR—KRAS—skin cancer	1.35e-05	0.000127	CbGpPWpGaD
Nicardipine—CALM1—Adaptive Immune System—NRAS—skin cancer	1.34e-05	0.000127	CbGpPWpGaD
Nicardipine—CALM2—Adaptive Immune System—NRAS—skin cancer	1.34e-05	0.000127	CbGpPWpGaD
Nicardipine—CALM1—Hemostasis—KRAS—skin cancer	1.34e-05	0.000126	CbGpPWpGaD
Nicardipine—CALM2—Hemostasis—KRAS—skin cancer	1.34e-05	0.000126	CbGpPWpGaD
Nicardipine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.33e-05	0.000126	CbGpPWpGaD
Nicardipine—CHRM1—Signaling Pathways—TERT—skin cancer	1.31e-05	0.000124	CbGpPWpGaD
Nicardipine—CHRM3—Signaling Pathways—TERT—skin cancer	1.31e-05	0.000123	CbGpPWpGaD
Nicardipine—CHRM2—Signaling Pathways—TERT—skin cancer	1.3e-05	0.000122	CbGpPWpGaD
Nicardipine—PDE1A—Signaling Pathways—KRAS—skin cancer	1.29e-05	0.000122	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling Pathways—TERT—skin cancer	1.29e-05	0.000122	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling by GPCR—KRAS—skin cancer	1.27e-05	0.00012	CbGpPWpGaD
Nicardipine—CALM3—Innate Immune System—KRAS—skin cancer	1.25e-05	0.000118	CbGpPWpGaD
Nicardipine—CALM3—Disease—BRAF—skin cancer	1.24e-05	0.000117	CbGpPWpGaD
Nicardipine—CALM3—Hemostasis—TP53—skin cancer	1.23e-05	0.000116	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling by GPCR—NRAS—skin cancer	1.23e-05	0.000116	CbGpPWpGaD
Nicardipine—CYP2C8—Metabolism—ERCC2—skin cancer	1.22e-05	0.000115	CbGpPWpGaD
Nicardipine—CALM2—Innate Immune System—KRAS—skin cancer	1.21e-05	0.000114	CbGpPWpGaD
Nicardipine—CALM1—Innate Immune System—KRAS—skin cancer	1.21e-05	0.000114	CbGpPWpGaD
Nicardipine—CHRM4—Signaling by GPCR—HRAS—skin cancer	1.2e-05	0.000113	CbGpPWpGaD
Nicardipine—CALM2—Disease—BRAF—skin cancer	1.2e-05	0.000113	CbGpPWpGaD
Nicardipine—CALM1—Disease—BRAF—skin cancer	1.2e-05	0.000113	CbGpPWpGaD
Nicardipine—CALM3—Adaptive Immune System—KRAS—skin cancer	1.2e-05	0.000113	CbGpPWpGaD
Nicardipine—CALM2—Hemostasis—TP53—skin cancer	1.19e-05	0.000112	CbGpPWpGaD
Nicardipine—CALM1—Hemostasis—TP53—skin cancer	1.19e-05	0.000112	CbGpPWpGaD
Nicardipine—PDE1B—Signaling Pathways—KRAS—skin cancer	1.18e-05	0.000112	CbGpPWpGaD
Nicardipine—CALM3—Hemostasis—HRAS—skin cancer	1.18e-05	0.000111	CbGpPWpGaD
Nicardipine—CALM1—Adaptive Immune System—KRAS—skin cancer	1.16e-05	0.000109	CbGpPWpGaD
Nicardipine—CALM2—Adaptive Immune System—KRAS—skin cancer	1.16e-05	0.000109	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling Pathways—BRAF—skin cancer	1.15e-05	0.000109	CbGpPWpGaD
Nicardipine—PDE1A—Signaling Pathways—TP53—skin cancer	1.15e-05	0.000108	CbGpPWpGaD
Nicardipine—CHRM5—Signaling by GPCR—HRAS—skin cancer	1.15e-05	0.000108	CbGpPWpGaD
Nicardipine—CHRM4—Signaling by GPCR—IL6—skin cancer	1.15e-05	0.000108	CbGpPWpGaD
Nicardipine—CALM2—Hemostasis—HRAS—skin cancer	1.14e-05	0.000107	CbGpPWpGaD
Nicardipine—CALM1—Hemostasis—HRAS—skin cancer	1.14e-05	0.000107	CbGpPWpGaD
Nicardipine—CYP3A4—Metabolism—ENO2—skin cancer	1.12e-05	0.000106	CbGpPWpGaD
Nicardipine—CHRM1—Signaling by GPCR—NRAS—skin cancer	1.11e-05	0.000104	CbGpPWpGaD
Nicardipine—CHRM3—Signaling by GPCR—NRAS—skin cancer	1.1e-05	0.000104	CbGpPWpGaD
Nicardipine—PDE1A—Signaling Pathways—HRAS—skin cancer	1.1e-05	0.000104	CbGpPWpGaD
Nicardipine—CHRM5—Signaling by GPCR—IL6—skin cancer	1.1e-05	0.000104	CbGpPWpGaD
Nicardipine—CALM3—Signaling Pathways—TERT—skin cancer	1.1e-05	0.000103	CbGpPWpGaD
Nicardipine—CHRM2—Signaling by GPCR—NRAS—skin cancer	1.09e-05	0.000103	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	1.09e-05	0.000103	CbGpPWpGaD
Nicardipine—CYP2C19—Metabolism—ERCC2—skin cancer	1.09e-05	0.000102	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling by GPCR—HRAS—skin cancer	1.08e-05	0.000102	CbGpPWpGaD
Nicardipine—CALM2—Signaling Pathways—TERT—skin cancer	1.06e-05	9.99e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling Pathways—TERT—skin cancer	1.06e-05	9.99e-05	CbGpPWpGaD
Nicardipine—CALM3—Innate Immune System—HRAS—skin cancer	1.06e-05	9.99e-05	CbGpPWpGaD
Nicardipine—ABCB1—Metabolism—ERCC2—skin cancer	1.06e-05	9.99e-05	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling by GPCR—KRAS—skin cancer	1.05e-05	9.95e-05	CbGpPWpGaD
Nicardipine—PDE1A—Signaling Pathways—IL6—skin cancer	1.05e-05	9.93e-05	CbGpPWpGaD
Nicardipine—PDE1B—Signaling Pathways—TP53—skin cancer	1.05e-05	9.92e-05	CbGpPWpGaD
Nicardipine—CHRM1—Signaling Pathways—BRAF—skin cancer	1.04e-05	9.8e-05	CbGpPWpGaD
Nicardipine—CHRM3—Signaling Pathways—BRAF—skin cancer	1.04e-05	9.77e-05	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling by GPCR—IL6—skin cancer	1.03e-05	9.75e-05	CbGpPWpGaD
Nicardipine—CHRM2—Signaling Pathways—BRAF—skin cancer	1.03e-05	9.68e-05	CbGpPWpGaD
Nicardipine—CALM2—Innate Immune System—HRAS—skin cancer	1.02e-05	9.66e-05	CbGpPWpGaD
Nicardipine—CALM1—Innate Immune System—HRAS—skin cancer	1.02e-05	9.66e-05	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling Pathways—BRAF—skin cancer	1.02e-05	9.65e-05	CbGpPWpGaD
Nicardipine—CALM3—Adaptive Immune System—HRAS—skin cancer	1.02e-05	9.59e-05	CbGpPWpGaD
Nicardipine—CALM3—Innate Immune System—IL6—skin cancer	1.01e-05	9.56e-05	CbGpPWpGaD
Nicardipine—PDE1B—Signaling Pathways—HRAS—skin cancer	1.01e-05	9.49e-05	CbGpPWpGaD
Nicardipine—CHRM3—Metabolism—PTGS2—skin cancer	1e-05	9.44e-05	CbGpPWpGaD
Nicardipine—CALM3—Disease—PTGS2—skin cancer	1e-05	9.44e-05	CbGpPWpGaD
Nicardipine—CYP2D6—Metabolism—ERCC2—skin cancer	9.98e-06	9.41e-05	CbGpPWpGaD
Nicardipine—CYP2C9—Metabolism—ERCC2—skin cancer	9.89e-06	9.33e-05	CbGpPWpGaD
Nicardipine—CALM2—Adaptive Immune System—HRAS—skin cancer	9.84e-06	9.28e-05	CbGpPWpGaD
Nicardipine—CALM1—Adaptive Immune System—HRAS—skin cancer	9.84e-06	9.28e-05	CbGpPWpGaD
Nicardipine—CALM2—Innate Immune System—IL6—skin cancer	9.81e-06	9.25e-05	CbGpPWpGaD
Nicardipine—CALM1—Innate Immune System—IL6—skin cancer	9.81e-06	9.25e-05	CbGpPWpGaD
Nicardipine—CHRM4—Signaling Pathways—NRAS—skin cancer	9.69e-06	9.14e-05	CbGpPWpGaD
Nicardipine—CALM2—Disease—PTGS2—skin cancer	9.68e-06	9.13e-05	CbGpPWpGaD
Nicardipine—CALM1—Disease—PTGS2—skin cancer	9.68e-06	9.13e-05	CbGpPWpGaD
Nicardipine—PDE1B—Signaling Pathways—IL6—skin cancer	9.63e-06	9.08e-05	CbGpPWpGaD
Nicardipine—CHRM1—Signaling by GPCR—KRAS—skin cancer	9.52e-06	8.98e-05	CbGpPWpGaD
Nicardipine—CHRM3—Signaling by GPCR—KRAS—skin cancer	9.49e-06	8.95e-05	CbGpPWpGaD
Nicardipine—CHRM2—Signaling by GPCR—KRAS—skin cancer	9.39e-06	8.86e-05	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	9.37e-06	8.84e-05	CbGpPWpGaD
Nicardipine—CHRM5—Signaling Pathways—NRAS—skin cancer	9.28e-06	8.75e-05	CbGpPWpGaD
Nicardipine—CALM3—Signaling by GPCR—NRAS—skin cancer	9.23e-06	8.7e-05	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling by GPCR—HRAS—skin cancer	8.96e-06	8.46e-05	CbGpPWpGaD
Nicardipine—CALM2—Signaling by GPCR—NRAS—skin cancer	8.93e-06	8.42e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling by GPCR—NRAS—skin cancer	8.93e-06	8.42e-05	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling Pathways—NRAS—skin cancer	8.72e-06	8.23e-05	CbGpPWpGaD
Nicardipine—CALM3—Signaling Pathways—BRAF—skin cancer	8.67e-06	8.18e-05	CbGpPWpGaD
Nicardipine—CYP2B6—Metabolism—PTGS2—skin cancer	8.61e-06	8.12e-05	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling by GPCR—IL6—skin cancer	8.58e-06	8.09e-05	CbGpPWpGaD
Nicardipine—CYP2E1—Metabolism—PTGS2—skin cancer	8.43e-06	7.95e-05	CbGpPWpGaD
Nicardipine—CALM3—Immune System—NRAS—skin cancer	8.43e-06	7.95e-05	CbGpPWpGaD
Nicardipine—CYP3A5—Metabolism—PTGS2—skin cancer	8.42e-06	7.94e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling Pathways—BRAF—skin cancer	8.39e-06	7.91e-05	CbGpPWpGaD
Nicardipine—CALM2—Signaling Pathways—BRAF—skin cancer	8.39e-06	7.91e-05	CbGpPWpGaD
Nicardipine—CALM3—Metabolism—PTGS2—skin cancer	8.38e-06	7.9e-05	CbGpPWpGaD
Nicardipine—CHRM4—Signaling Pathways—KRAS—skin cancer	8.34e-06	7.86e-05	CbGpPWpGaD
Nicardipine—CALM2—Immune System—NRAS—skin cancer	8.16e-06	7.69e-05	CbGpPWpGaD
Nicardipine—CALM1—Immune System—NRAS—skin cancer	8.16e-06	7.69e-05	CbGpPWpGaD
Nicardipine—CALM2—Metabolism—PTGS2—skin cancer	8.11e-06	7.65e-05	CbGpPWpGaD
Nicardipine—CALM1—Metabolism—PTGS2—skin cancer	8.11e-06	7.65e-05	CbGpPWpGaD
Nicardipine—CHRM1—Signaling by GPCR—HRAS—skin cancer	8.09e-06	7.63e-05	CbGpPWpGaD
Nicardipine—CHRM3—Signaling by GPCR—HRAS—skin cancer	8.06e-06	7.61e-05	CbGpPWpGaD
Nicardipine—CHRM2—Signaling by GPCR—HRAS—skin cancer	7.98e-06	7.53e-05	CbGpPWpGaD
Nicardipine—CHRM5—Signaling Pathways—KRAS—skin cancer	7.98e-06	7.53e-05	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	7.96e-06	7.51e-05	CbGpPWpGaD
Nicardipine—CALM3—Signaling by GPCR—KRAS—skin cancer	7.94e-06	7.49e-05	CbGpPWpGaD
Nicardipine—CALM3—Disease—NRAS—skin cancer	7.78e-06	7.34e-05	CbGpPWpGaD
Nicardipine—CHRM1—Signaling by GPCR—IL6—skin cancer	7.74e-06	7.3e-05	CbGpPWpGaD
Nicardipine—CHRM3—Signaling by GPCR—IL6—skin cancer	7.72e-06	7.28e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling by GPCR—KRAS—skin cancer	7.68e-06	7.25e-05	CbGpPWpGaD
Nicardipine—CALM2—Signaling by GPCR—KRAS—skin cancer	7.68e-06	7.25e-05	CbGpPWpGaD
Nicardipine—CHRM2—Signaling by GPCR—IL6—skin cancer	7.64e-06	7.21e-05	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling by GPCR—IL6—skin cancer	7.62e-06	7.19e-05	CbGpPWpGaD
Nicardipine—CALM1—Disease—NRAS—skin cancer	7.53e-06	7.1e-05	CbGpPWpGaD
Nicardipine—CALM2—Disease—NRAS—skin cancer	7.53e-06	7.1e-05	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling Pathways—KRAS—skin cancer	7.51e-06	7.08e-05	CbGpPWpGaD
Nicardipine—CHRM4—Signaling Pathways—TP53—skin cancer	7.41e-06	6.99e-05	CbGpPWpGaD
Nicardipine—CYP2C8—Metabolism—PTGS2—skin cancer	7.29e-06	6.88e-05	CbGpPWpGaD
Nicardipine—CALM3—Immune System—KRAS—skin cancer	7.26e-06	6.84e-05	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling Pathways—NRAS—skin cancer	7.24e-06	6.83e-05	CbGpPWpGaD
Nicardipine—CHRM5—Signaling Pathways—TP53—skin cancer	7.1e-06	6.69e-05	CbGpPWpGaD
Nicardipine—CHRM4—Signaling Pathways—HRAS—skin cancer	7.09e-06	6.68e-05	CbGpPWpGaD
Nicardipine—CALM2—Immune System—KRAS—skin cancer	7.02e-06	6.62e-05	CbGpPWpGaD
Nicardipine—CALM1—Immune System—KRAS—skin cancer	7.02e-06	6.62e-05	CbGpPWpGaD
Nicardipine—CHRM5—Signaling Pathways—HRAS—skin cancer	6.79e-06	6.4e-05	CbGpPWpGaD
Nicardipine—CHRM4—Signaling Pathways—IL6—skin cancer	6.78e-06	6.4e-05	CbGpPWpGaD
Nicardipine—CALM3—Signaling by GPCR—HRAS—skin cancer	6.75e-06	6.37e-05	CbGpPWpGaD
Nicardipine—CALM3—Disease—KRAS—skin cancer	6.7e-06	6.32e-05	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling Pathways—TP53—skin cancer	6.67e-06	6.29e-05	CbGpPWpGaD
Nicardipine—CHRM1—Signaling Pathways—NRAS—skin cancer	6.53e-06	6.16e-05	CbGpPWpGaD
Nicardipine—CALM2—Signaling by GPCR—HRAS—skin cancer	6.53e-06	6.16e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling by GPCR—HRAS—skin cancer	6.53e-06	6.16e-05	CbGpPWpGaD
Nicardipine—CYP3A4—Metabolism—ERCC2—skin cancer	6.52e-06	6.15e-05	CbGpPWpGaD
Nicardipine—CHRM3—Signaling Pathways—NRAS—skin cancer	6.51e-06	6.14e-05	CbGpPWpGaD
Nicardipine—CYP2C19—Metabolism—PTGS2—skin cancer	6.51e-06	6.14e-05	CbGpPWpGaD
Nicardipine—CHRM5—Signaling Pathways—IL6—skin cancer	6.5e-06	6.13e-05	CbGpPWpGaD
Nicardipine—CALM1—Disease—KRAS—skin cancer	6.48e-06	6.11e-05	CbGpPWpGaD
Nicardipine—CALM2—Disease—KRAS—skin cancer	6.48e-06	6.11e-05	CbGpPWpGaD
Nicardipine—CALM3—Signaling by GPCR—IL6—skin cancer	6.46e-06	6.09e-05	CbGpPWpGaD
Nicardipine—CHRM2—Signaling Pathways—NRAS—skin cancer	6.45e-06	6.08e-05	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling Pathways—NRAS—skin cancer	6.43e-06	6.06e-05	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling Pathways—HRAS—skin cancer	6.38e-06	6.02e-05	CbGpPWpGaD
Nicardipine—ABCB1—Metabolism—PTGS2—skin cancer	6.35e-06	5.99e-05	CbGpPWpGaD
Nicardipine—CALM2—Signaling by GPCR—IL6—skin cancer	6.25e-06	5.9e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling by GPCR—IL6—skin cancer	6.25e-06	5.9e-05	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling Pathways—KRAS—skin cancer	6.23e-06	5.88e-05	CbGpPWpGaD
Nicardipine—CALM3—Immune System—HRAS—skin cancer	6.17e-06	5.82e-05	CbGpPWpGaD
Nicardipine—ADRA1D—Signaling Pathways—IL6—skin cancer	6.11e-06	5.76e-05	CbGpPWpGaD
Nicardipine—CYP2D6—Metabolism—PTGS2—skin cancer	5.98e-06	5.64e-05	CbGpPWpGaD
Nicardipine—CALM2—Immune System—HRAS—skin cancer	5.97e-06	5.63e-05	CbGpPWpGaD
Nicardipine—CALM1—Immune System—HRAS—skin cancer	5.97e-06	5.63e-05	CbGpPWpGaD
Nicardipine—CYP2C9—Metabolism—PTGS2—skin cancer	5.93e-06	5.6e-05	CbGpPWpGaD
Nicardipine—CALM3—Immune System—IL6—skin cancer	5.9e-06	5.57e-05	CbGpPWpGaD
Nicardipine—CALM2—Immune System—IL6—skin cancer	5.71e-06	5.39e-05	CbGpPWpGaD
Nicardipine—CALM1—Immune System—IL6—skin cancer	5.71e-06	5.39e-05	CbGpPWpGaD
Nicardipine—CALM3—Disease—HRAS—skin cancer	5.69e-06	5.37e-05	CbGpPWpGaD
Nicardipine—CHRM1—Signaling Pathways—KRAS—skin cancer	5.62e-06	5.3e-05	CbGpPWpGaD
Nicardipine—CHRM3—Signaling Pathways—KRAS—skin cancer	5.6e-06	5.29e-05	CbGpPWpGaD
Nicardipine—CHRM2—Signaling Pathways—KRAS—skin cancer	5.55e-06	5.23e-05	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling Pathways—TP53—skin cancer	5.54e-06	5.22e-05	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling Pathways—KRAS—skin cancer	5.53e-06	5.22e-05	CbGpPWpGaD
Nicardipine—CALM2—Disease—HRAS—skin cancer	5.51e-06	5.2e-05	CbGpPWpGaD
Nicardipine—CALM1—Disease—HRAS—skin cancer	5.51e-06	5.2e-05	CbGpPWpGaD
Nicardipine—CALM3—Signaling Pathways—NRAS—skin cancer	5.45e-06	5.14e-05	CbGpPWpGaD
Nicardipine—CALM3—Disease—IL6—skin cancer	5.45e-06	5.14e-05	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling Pathways—HRAS—skin cancer	5.3e-06	5e-05	CbGpPWpGaD
Nicardipine—CALM2—Signaling Pathways—NRAS—skin cancer	5.27e-06	4.97e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling Pathways—NRAS—skin cancer	5.27e-06	4.97e-05	CbGpPWpGaD
Nicardipine—CALM2—Disease—IL6—skin cancer	5.27e-06	4.97e-05	CbGpPWpGaD
Nicardipine—CALM1—Disease—IL6—skin cancer	5.27e-06	4.97e-05	CbGpPWpGaD
Nicardipine—ADRA1B—Signaling Pathways—IL6—skin cancer	5.07e-06	4.78e-05	CbGpPWpGaD
Nicardipine—CHRM1—Signaling Pathways—TP53—skin cancer	5e-06	4.71e-05	CbGpPWpGaD
Nicardipine—CHRM3—Signaling Pathways—TP53—skin cancer	4.98e-06	4.7e-05	CbGpPWpGaD
Nicardipine—CHRM2—Signaling Pathways—TP53—skin cancer	4.93e-06	4.65e-05	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling Pathways—TP53—skin cancer	4.92e-06	4.64e-05	CbGpPWpGaD
Nicardipine—CHRM1—Signaling Pathways—HRAS—skin cancer	4.78e-06	4.51e-05	CbGpPWpGaD
Nicardipine—CHRM3—Signaling Pathways—HRAS—skin cancer	4.76e-06	4.49e-05	CbGpPWpGaD
Nicardipine—CHRM2—Signaling Pathways—HRAS—skin cancer	4.72e-06	4.45e-05	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling Pathways—HRAS—skin cancer	4.7e-06	4.44e-05	CbGpPWpGaD
Nicardipine—CALM3—Signaling Pathways—KRAS—skin cancer	4.69e-06	4.43e-05	CbGpPWpGaD
Nicardipine—CHRM1—Signaling Pathways—IL6—skin cancer	4.57e-06	4.31e-05	CbGpPWpGaD
Nicardipine—CHRM3—Signaling Pathways—IL6—skin cancer	4.56e-06	4.3e-05	CbGpPWpGaD
Nicardipine—CALM2—Signaling Pathways—KRAS—skin cancer	4.54e-06	4.28e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling Pathways—KRAS—skin cancer	4.54e-06	4.28e-05	CbGpPWpGaD
Nicardipine—CHRM2—Signaling Pathways—IL6—skin cancer	4.51e-06	4.26e-05	CbGpPWpGaD
Nicardipine—ADRA1A—Signaling Pathways—IL6—skin cancer	4.5e-06	4.25e-05	CbGpPWpGaD
Nicardipine—CALM3—Signaling Pathways—TP53—skin cancer	4.17e-06	3.93e-05	CbGpPWpGaD
Nicardipine—CALM2—Signaling Pathways—TP53—skin cancer	4.03e-06	3.8e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling Pathways—TP53—skin cancer	4.03e-06	3.8e-05	CbGpPWpGaD
Nicardipine—CALM3—Signaling Pathways—HRAS—skin cancer	3.99e-06	3.76e-05	CbGpPWpGaD
Nicardipine—CYP3A4—Metabolism—PTGS2—skin cancer	3.91e-06	3.69e-05	CbGpPWpGaD
Nicardipine—CALM2—Signaling Pathways—HRAS—skin cancer	3.86e-06	3.64e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling Pathways—HRAS—skin cancer	3.86e-06	3.64e-05	CbGpPWpGaD
Nicardipine—CALM3—Signaling Pathways—IL6—skin cancer	3.82e-06	3.6e-05	CbGpPWpGaD
Nicardipine—CALM2—Signaling Pathways—IL6—skin cancer	3.69e-06	3.48e-05	CbGpPWpGaD
Nicardipine—CALM1—Signaling Pathways—IL6—skin cancer	3.69e-06	3.48e-05	CbGpPWpGaD
